vs
Side-by-side financial comparison of BayFirst Financial Corp. (BAFN) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $10.3M, roughly 1.8× BayFirst Financial Corp.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -55.0%, a 54.1% gap on every dollar of revenue. Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -29.6%).
The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BAFN vs CTMX — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.3M | $18.7M |
| Net Profit | $-5.7M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | — | -6.9% |
| Net Margin | -55.0% | -0.8% |
| Revenue YoY | — | -25.7% |
| Net Profit YoY | -130.6% | 97.6% |
| EPS (diluted) | $-1.48 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $10.3M | — | ||
| Q4 25 | $11.2M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $23.1M | $18.7M | ||
| Q1 25 | $19.8M | $50.9M | ||
| Q4 24 | $32.9M | $38.1M | ||
| Q3 24 | $21.7M | $33.4M | ||
| Q2 24 | $20.8M | $25.1M |
| Q1 26 | $-5.7M | — | ||
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $-18.9M | — | ||
| Q2 25 | $-1.2M | $-154.0K | ||
| Q1 25 | $-335.0K | $23.5M | ||
| Q4 24 | $9.8M | $18.9M | ||
| Q3 24 | $1.1M | $5.7M | ||
| Q2 24 | $866.0K | $-6.5M |
| Q1 26 | — | — | ||
| Q4 25 | -25.3% | — | ||
| Q3 25 | -253.0% | — | ||
| Q2 25 | -7.1% | -6.9% | ||
| Q1 25 | -2.3% | 44.4% | ||
| Q4 24 | — | 46.4% | ||
| Q3 24 | 7.1% | 12.3% | ||
| Q2 24 | 5.9% | -33.7% |
| Q1 26 | -55.0% | — | ||
| Q4 25 | -22.1% | — | ||
| Q3 25 | -184.7% | — | ||
| Q2 25 | -5.3% | -0.8% | ||
| Q1 25 | -1.7% | 46.2% | ||
| Q4 24 | 91.8% | 49.6% | ||
| Q3 24 | 5.2% | 17.2% | ||
| Q2 24 | 4.2% | -26.0% |
| Q1 26 | $-1.48 | — | ||
| Q4 25 | $-0.71 | — | ||
| Q3 25 | $-4.66 | — | ||
| Q2 25 | $-0.39 | — | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | $2.21 | — | ||
| Q3 24 | $0.18 | — | ||
| Q2 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $134.5M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $81.9M | $119.9M |
| Total Assets | $1.2B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $134.5M | — | ||
| Q4 25 | $207.0M | — | ||
| Q3 25 | $118.5M | — | ||
| Q2 25 | $77.3M | $49.0M | ||
| Q1 25 | $63.2M | $47.6M | ||
| Q4 24 | $77.8M | $38.1M | ||
| Q3 24 | $64.4M | $40.6M | ||
| Q2 24 | $60.8M | $43.2M |
| Q1 26 | $81.9M | — | ||
| Q4 25 | $87.6M | — | ||
| Q3 25 | $89.7M | — | ||
| Q2 25 | $108.2M | $119.9M | ||
| Q1 25 | $110.1M | $25.0M | ||
| Q4 24 | $110.9M | $-456.0K | ||
| Q3 24 | $102.3M | $-23.5M | ||
| Q2 24 | $101.0M | $-31.2M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | $175.1M | ||
| Q1 25 | $1.3B | $98.5M | ||
| Q4 24 | $1.3B | $120.5M | ||
| Q3 24 | $1.2B | $139.0M | ||
| Q2 24 | $1.2B | $159.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $285.3M | — | ||
| Q3 25 | $47.3M | — | ||
| Q2 25 | $63.3M | $-15.8M | ||
| Q1 25 | $74.2M | $-21.0M | ||
| Q4 24 | $390.5M | $-19.9M | ||
| Q3 24 | $90.8M | $-20.7M | ||
| Q2 24 | $78.8M | $-19.5M |
| Q1 26 | — | — | ||
| Q4 25 | $285.0M | — | ||
| Q3 25 | $47.3M | — | ||
| Q2 25 | $63.1M | $-15.8M | ||
| Q1 25 | $74.1M | $-21.2M | ||
| Q4 24 | $388.8M | $-20.0M | ||
| Q3 24 | $90.5M | $-20.7M | ||
| Q2 24 | $78.4M | $-19.6M |
| Q1 26 | — | — | ||
| Q4 25 | 2554.2% | — | ||
| Q3 25 | 462.2% | — | ||
| Q2 25 | 272.7% | -84.6% | ||
| Q1 25 | 375.1% | -41.6% | ||
| Q4 24 | 1180.9% | -52.5% | ||
| Q3 24 | 416.5% | -62.1% | ||
| Q2 24 | 376.1% | -78.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 5.1% | 0.2% | ||
| Q3 24 | 1.5% | 0.1% | ||
| Q2 24 | 1.9% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | 39.95× | -1.05× | ||
| Q3 24 | 79.85× | -3.61× | ||
| Q2 24 | 90.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAFN
| Net Interest Income | $9.4M | 91% |
| Noninterest Income | $884.0K | 9% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
